122 related articles for article (PubMed ID: 26169620)
21. [How I treat relapsed/transformed follicular lymphoma].
Xu B; Lin ZJ
Zhonghua Xue Ye Xue Za Zhi; 2023 Dec; 44(12):983-988. PubMed ID: 38503520
[No Abstract] [Full Text] [Related]
22. Histological transformation and secondary malignancies in follicular lymphoma.
Vitolo U; Chiappella A
Lancet Haematol; 2018 Nov; 5(11):e496-e497. PubMed ID: 30389030
[No Abstract] [Full Text] [Related]
23. Rituximab for follicular non-Hodgkin lymphoma.
Gajraj E; Chung H; Longson C; Stevens A
Lancet Oncol; 2008 Apr; 9(4):320-1. PubMed ID: 18405852
[No Abstract] [Full Text] [Related]
24. Survival in elderly follicular lymphoma patients who receive frontline chemo-immunotherapy.
Griffiths R; Gleeson M; Reyes C; Knopf K; Danese M
Am J Hematol; 2010 Dec; 85(12):963-7. PubMed ID: 20981680
[No Abstract] [Full Text] [Related]
25. Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients.
Sacchi S; Pozzi S; Marcheselli L; Bari A; Luminari S; Angrilli F; Merli F; Vallisa D; Baldini L; Brugiatelli M;
Cancer; 2007 May; 109(10):2077-82. PubMed ID: 17394190
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: a randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA).
Ribrag V; Tilly H; Casasnovas O; Bosly A; Bouabdallah R; Delarue R; Boue F; Bron D; Feugier P; Haioun C; Offner F; Coiffier B
Eur J Cancer; 2013 Mar; 49(4):904-10. PubMed ID: 23273434
[TBL] [Abstract][Full Text] [Related]
27. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03.
Taverna C; Martinelli G; Hitz F; Mingrone W; Pabst T; Cevreska L; Del Giglio A; Vanazzi A; Laszlo D; Raats J; Rauch D; Vorobiof DA; Lohri A; Biaggi Rudolf C; Rondeau S; Rusterholz C; Heijnen IA; Zucca E; Ghielmini M
J Clin Oncol; 2016 Feb; 34(5):495-500. PubMed ID: 26712227
[TBL] [Abstract][Full Text] [Related]
28. Fludarabine, cyclophosphamide and rituximab as first-line treatment in patients with newly diagnosed follicular lymphoma.
De la Cruz Vicente F; Carrillo-Cruz E; Rodriguez MS; Marín Niebla A; Galiana ML; Gonzalez JF; Cuadrado IM; Campos JG; Tocino IE; Rios-Herranz E; Perez-Simón JA
Eur J Haematol; 2014 Dec; 93(6):469-75. PubMed ID: 24853381
[TBL] [Abstract][Full Text] [Related]
29. Maintenance rituximab should be considered for patients with follicular lymphoma.
Barr PM
Clin Adv Hematol Oncol; 2014 Aug; 12(8):541-3. PubMed ID: 25356579
[No Abstract] [Full Text] [Related]
30. Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi.
Luminari S; Galimberti S; Versari A; Biasoli I; Anastasia A; Rusconi C; Ferrari A; Petrini M; Manni M; Federico M
Haematologica; 2016 Feb; 101(2):e66-8. PubMed ID: 26471485
[No Abstract] [Full Text] [Related]
31. Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study.
Bachy E; Estell JA; Van de Neste E; Bouabdallah R; Bargay J; Delmer A; Gelas-Dore B; Gomes da Silva M; Fitoussi O; Belada D; Maisonneuve H; Intragumtornchai T; Lamy T; Dartigues P; Seymour JF; Salles G
Am J Hematol; 2016 Jun; 91(4):410-5. PubMed ID: 26799234
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study.
Salles G; Schuster SJ; de Vos S; Wagner-Johnston ND; Viardot A; Blum KA; Flowers CR; Jurczak WJ; Flinn IW; Kahl BS; Martin P; Kim Y; Shreay S; Will M; Sorensen B; Breuleux M; Zinzani PL; Gopal AK
Haematologica; 2017 Apr; 102(4):e156-e159. PubMed ID: 27979923
[No Abstract] [Full Text] [Related]
33. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
[TBL] [Abstract][Full Text] [Related]
34. Prolonged disease-free survival and overall survival with CVP alternating with fludarabine in advanced follicular lymphoma.
Ai WZ; Kohrt HE; Timmerman J; Hwang J; Hsu FJ; Czerwinski DD; Taidi B; Levy R
Am J Hematol; 2011 Jun; 86(6):515-8. PubMed ID: 21538469
[No Abstract] [Full Text] [Related]
35. Rituximab Improves the Outcome of Patients With Grade 3 Follicular Lymphoma Receiving Anthracycline-Based Therapy.
Yuan J; Greiner TC; Fu K; Smith LM; Aoun P; Chan WC; Bierman PJ; Bociek RG; Vose JM; Armitage JO; Weisenburger DD
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):488-497.e2. PubMed ID: 28842137
[TBL] [Abstract][Full Text] [Related]
36. Absolute monocyte count in follicular lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Watanabe R; Tomita N; Kishimoto K; Koyama S; Ogusa E; Ishii Y; Miyashita K; Matsuura S; Fujisawa S; Hattori Y; Takasaki H; Fujita A; Ohshima R; Kuwabara H; Hashimoto C; Fujimaki K; Sakai R; Ishigatsubo Y
Leuk Res; 2013 Oct; 37(10):1208-12. PubMed ID: 23927994
[TBL] [Abstract][Full Text] [Related]
37. [Prognostic factors of follicular lymphoma treated with combination chemotherapy].
Niitsu N; Umeda M
Rinsho Ketsueki; 1997 Jun; 38(6):496-504. PubMed ID: 9248325
[TBL] [Abstract][Full Text] [Related]
38. Randomized controlled trials in relapsed/refractory follicular lymphoma: a systematic review and meta-analysis.
Police RL; Trask PC; Wang J; Olivares R; Khan S; Abbe A; Colosia A; Njue A; Sherril B; Ruiz-Soto R; Kaye JA; Hamadani M
J Oncol Pharm Pract; 2016 Oct; 22(5):666-78. PubMed ID: 26320127
[TBL] [Abstract][Full Text] [Related]
39. Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial.
Ladetto M; Vallet S; Benedetti F; Vitolo U; Martelli M; Callea V; Patti C; Coser P; Perrotti A; Sorio M; Boccomini C; Pulsoni A; Stelitano C; Scimè R; Boccadoro M; Rosato R; De Marco F; Zanni M; Corradini P; Tarella C
Leukemia; 2006 Oct; 20(10):1840-7. PubMed ID: 16932351
[TBL] [Abstract][Full Text] [Related]
40. The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study.
Rossi D; Bruscaggin A; La Cava P; Galimberti S; Ciabatti E; Luminari S; Rigacci L; Tucci A; Pulsoni A; Bertoldero G; Vallisa D; Rusconi C; Spina M; Arcaini L; Angrilli F; Stelitano C; Merli F; Gaidano G; Federico M; Palumbo GA
Haematologica; 2015 Apr; 100(4):517-24. PubMed ID: 25596266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]